홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
Heatmap
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
CVKD
#4818
Cadrenal Therapeutics, Inc. Common Stock
4.8
1
USD
+0.42%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
+0.42%
월간 변동
-35.26%
6달 변화
-12.86%
년간 변동율
-12.86%
이전 종가
4.7
9
Open
4.8
1
Bid
Ask
Low
4.8
1
High
4.8
1
양
2
마켓
주식
헬스케어
CVKD
Open full chart
Financials
Overview
성명
Statistics
Quarterly
Annual
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
1.88 M
1.97 M
2.05 M
2.08 M
2.51 M
—
Valuation ratios
Enterprise value
17.24 M
27.34 M
19.66 M
24.85 M
12.99 M
84.84 M
Price to earnings ratio
-1.66
-1.9
-1.36
-1.72
-1.02
-6
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
-2.4
-2.38
-1.6
-2.07
-1.07
-7.12
Price to book ratio
2.38
1.09
0.82
1.07
4.94
7.91
EBITDA 비율에 대한 기업 가치
-1.57
—
—
—
—
—
Profitability ratios
Return on assets %
-0.41
-0.48
-0.61
-0.66
-0.7
-2.46
Return on equity %
-0.56
-0.63
-0.85
-0.98
-1.11
-3.57
Return on invested capital %
-173.12 K
—
—
—
-44.46 K
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
3.77
4.32
3.56
3.02
2.72
13.61
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-1.47
-2.52
-1.54
-1.15
-1.29
-6.51
EBIT per share
-3.51
—
—
—
—
—
EBITDA per share
-3.51
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
8.2
3.98
2.84
1.89
2.01
10.72
Net current asset value per share
8.29
4.31
3.04
2
2.17
11.52
Tangible book value per share
6.1
3.31
2.19
1.34
1.37
8.22
Working capital per share
6.09
3.31
2.19
1.33
1.37
8.2
Book value per share
6.1
3.31
2.19
1.34
1.37
8.22
뉴스
Cadrenal schedules FDA meeting for HIT drug CAD-1005
카데레날 테라퓨틱스, 2상 임상 결과 발표 후 주가 급등
Cadrenal Therapeutics stock surges on Phase 2 trial results
카드레날, HIT 임상시험서 CAD-1005 혈전 감소 효과 보여
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial
카드레날, 혈액 질환 치료제 ’12-LOX 억제제’ 잠재력 강조
Cadrenal highlights potential of 12-LOX inhibitor for blood disorder
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc.
캐드레날 테라퓨틱스 CFO Szot, 주식 1496달러 상당 매도